Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin in STEMI
NCT06619600Phase 3Active, not recruiting
- Sponsor
- Hospital Clínic de Barcelona
- Start
- May 2021
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of dapagliflozin in ST-segment elevation myocardial infarction (STEMI), sponsored by Hospital Clínic de Barcelona. Started May 2021; status: active, not recruiting.
02
Drugs
dapagliflozin
03
Conditions
ST-segment elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NCT06619600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06619600.